Report: Biopharma's class of 2013 is laden with blockbusters

While 2013's number of approved drugs fell short of 2012's record haul, the class is likely to more than make up for that disparity in the dollar column, according to EvaluatePharma. Nine drugs approved last year, led by Gilead Sciences' ($GILD) soaring hepatitis C treatment Sovaldi, will crack the blockbuster barrier by 2018, according to a new report. By 2018, last year's crop of drugs should bring in an annual $24.4 billion, EvaluatePharma says, 40% above 2012's peak. More